Method for long-term decrease of intraocular pressure
It is estimated that in the US alone, approximately 3 million individuals are living with glaucoma, making it the leading cause of blindness in the US. There currently is no cure for glaucoma, but reducing intraocular pressure (eye pressure) has proven an effective treatment. Reducing intraocular pressure currently requires either invasive laser surgery or medication. Medication is most common, but patient adherence is low due to the need for daily doses. There is an unmet need to develop new medications that are taken less regularly, specifically for glaucoma.
Dr. Gonzalez and co-workers have developed a gene therapy that reduces intraocular pressure. This technology is intended to treat glaucoma patients and improve patient adherence. The therapy is an adenovirus delivery system of an important microRNA. In an animal model expressing this microRNA through adenoviral and lentiviral delivery, the microRNA expression decreased intraocular pressure in rats for up to two to three months at levels comparable to current treatments.
- Decrease intraocular pressure in the eye at similar levels of current marketed medications
- Long-term decrease of intraocular pressure of up to three months
- No eye abnormalities in animal models were observed after microRNA expression